Devon L. Graham

Devon L. Graham

Auto-generated profile, based on publicly available information

Devon L. Graham

Department of Biomedical Sciences, Florida State University College of Medicine, Tallahassee, FL, 32306, USA; Institute for Pediatric Rare Diseases, Florida State University College of Medicine, Tallahassee, FL, 32306, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2014 in Neuropsychopharmacology
Verified
Journal Article
Closed access
EREmily J Ross
Emily J Ross
DGDevon L Graham
Devon L Graham
KMKelli M Money
Kelli M Money
GSGregg D Stanwood
Gregg D Stanwood

1 October 2015 in Physiology & Behavior
Verified
Journal Article
Closed access
GSGunnar Sørensen
Gunnar Sørensen
IRIndia A. Reddy
India A. Reddy
PWPia Weikop
Pia Weikop
DGDevon L. Graham
Devon L. Graham
GSGregg D. Stanwood
Gregg D. Stanwood
AFAnders Fink-Jensen
Anders Fink-Jensen

13 January 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MSMatthew Skelton
Matthew Skelton
TSTori L Schaefer
Tori L Schaefer
DGDevon L Graham
Devon L Graham
TDTon J Degrauw
Ton J Degrauw
JCJoseph F Clark
Joseph F Clark
CVCharles V. Vorhees
Charles V. Vorhees
Mutations in the creatine (Cr) transporter (CrT; Slc6a8) gene lead to absence of brain Cr and intellectual disabilities, loss of speech, and behavioral abnormalities. To date, no mouse model of CrT deficiency exists in which to understand and develop treatments for this condition. The purpose of this study was to generate a mouse model of human CrT deficiency. We created mice with exons 2–4 of Slc6a8 flanked by loxP sites and crossed these to Cre:CMV mice to create a line of ubiquitous CrT knockout expressing mice. Mice were tested for learning and memory deficits and assayed for Cr and neurotransmitter levels. Male CrT−/y (affected) mice lack Cr in the brain and muscle with significant reductions of Cr in other tissues including heart and testes. CrT−/y mice showed increased path length during acquisition and reversal learning in the Morris water maze. During probe trials, CrT−/y mice showed increased average distance from the platform site. CrT−/y mice showed reduced novel object recognition and conditioned fear memory compared to CrT+/y. CrT−/y mice had increased serotonin and 5-hydroxyindole acetic acid in the hippocampus and prefrontal cortex. Ubiquitous CrT knockout mice have learning and memory deficits resembling human CrT deficiency and this model should be useful in understanding this disorder.

6 January 2015 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
AFA L Frederick
A L Frederick
HYHideaki Yano
Hideaki Yano
PTP Trifilieff
P Trifilieff
HVH D Vishwasrao
H D Vishwasrao
DBD Biezonski
D Biezonski
JJJ A Javitch
J A Javitch
Hetero-oligomers of G-protein-coupled receptors have become the subject of intense investigation, because their purported potential to manifest signaling and pharmacological properties that differ from the component receptors makes them highly attractive for the development of more selective pharmacological treatments. In particular, dopamine D1 and D2 receptors have been proposed to form hetero-oligomers that couple to Gαq proteins, and SKF83959 has been proposed to act as a biased agonist that selectively engages these receptor complexes to activate Gαq and thus phospholipase C. D1/D2 heteromers have been proposed as relevant to the pathophysiology and treatment of depression and schizophrenia. We used in vitro bioluminescence resonance energy transfer, ex vivo analyses of receptor localization and proximity in brain slices, and behavioral assays in mice to characterize signaling from these putative dimers/oligomers. We were unable to detect Gαq or Gα11 protein coupling to homomers or heteromers of D1 or D2 receptors using a variety of biosensors. SKF83959-induced locomotor and grooming behaviors were eliminated in D1 receptor knockout (KO) mice, verifying a key role for D1-like receptor activation. In contrast, SKF83959-induced motor responses were intact in D2 receptor and Gαq KO mice, as well as in knock-in mice expressing a mutant Ala286-CaMKIIα that cannot autophosphorylate to become active. Moreover, we found that, in the shell of the nucleus accumbens, even in neurons in which D1 and D2 receptor promoters are both active, the receptor proteins are segregated and do not form complexes. These data are not compatible with SKF83959 signaling through Gαq or through a D1/D2 heteromer and challenge the existence of such a signaling complex in the adult animals that we used for our studies.

23 October 2012 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
DGD L Graham
D L Graham
KEK Erreger
K Erreger
AGA Galli
A Galli
GSG D Stanwood
G D Stanwood
Alprazolam also reduced thalamic and midbrain perfusion. In prior Positron Emission Tomography (PET) studies, thalamic and midbrain metabolism correlated with sedative effects of benzodiazepines and general anesthetics, 9,10 a relationship potentially reflected here in slowed task reaction times. This is the first study using ASL perfusion MRI to characterize benzodiazepine effects in human brain. Notably, prior PET studies did not reveal increased accumbens perfusion. The current study likely has greater sensitivity due to its larger sample size, although other methodological factors may also contribute (see Supplementary discussion). ASL perfusion MRI provides unique advantages as a biomarker of drug actions in the brain: it is noninvasive, non-radioactive, and easily included in multimodal MRI protocols. 4-6 Our findings suggest a plausible neurobiological mechanism for some of the most commonly observed effects of benzodiazepines, supporting the use of ASL perfusion in developing drugs targeting specific neural circuits to ameliorate psychiatric symptoms.

17 May 2016 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
IRI A Reddy
I A Reddy
JPJ A Pino
J A Pino
PWP Weikop
P Weikop
NON Osses
N Osses
GSG Sørensen
G Sørensen
AGA Galli
A Galli
Agonism of the glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) has been effective at treating aspects of addictive behavior for a number of abused substances, including cocaine. However, the molecular mechanisms and brain circuits underlying the therapeutic effects of GLP-1R signaling on cocaine actions remain elusive. Recent evidence has revealed that endogenous signaling at the GLP-1R within the forebrain lateral septum (LS) acts to reduce cocaine-induced locomotion and cocaine conditioned place preference, both considered dopamine (DA)-associated behaviors. DA terminals project from the ventral tegmental area to the LS and express the DA transporter (DAT). Cocaine acts by altering DA bioavailability by targeting the DAT. Therefore, GLP-1R signaling might exert effects on DAT to account for its regulation of cocaine-induced behaviors. We show that the GLP-1R is highly expressed within the LS. GLP-1, in LS slices, significantly enhances DAT surface expression and DAT function. Exenatide (Ex-4), a long-lasting synthetic analog of GLP-1 abolished cocaine-induced elevation of DA. Interestingly, acute administration of Ex-4 reduces septal expression of the retrograde messenger 2-arachidonylglycerol (2-AG), as well as a product of its presynaptic degradation, arachidonic acid (AA). Notably, AA reduces septal DAT function pointing to AA as a novel regulator of central DA homeostasis. We further show that AA oxidation product γ-ketoaldehyde (γ-KA) forms adducts with the DAT and reduces DAT plasma membrane expression and function. These results support a mechanism in which postsynaptic septal GLP-1R activation regulates 2-AG levels to alter presynaptic DA homeostasis and cocaine actions through AA.